Search clinical trials for: Remodulin (treprostinil sodium)

Total 10521 results

United Therapeutics

Terminated

Study of Remodulin in Patients With Critical Limb Ischemia With No Planned Revascularization Procedures

Peripheral Vascular Disease | Critical Limb Ischemia | Foot Ulcers | Rest Leg Pain

United States
United Therapeutics

Terminated

Effects of Remodulin in Patients With Critical Limb Ischemia Following a Vein Bypass Graft

Peripheral Vascular Disease

United States
United Therapeutics

Withdrawn

Safety of Transition From Selexipag to Remodulin® Then Oral Treprostinil in Symptomatic Adult PAH

Pulmonary Arterial Hypertension
United Therapeutics
Asian Clinical Trials

Terminated

Study of Intravenous Remodulin in Patients in India With Pulmonary Arterial Hypertension (TRUST-1)

Pulmonary Arterial Hypertension

India
United Therapeutics

Terminated

Rapid Switch From Flolan to Remodulin in the Outpatient Clinic

Hypertension, Pulmonary

United States
United Therapeutics

Completed

Safety, Efficacy and Treatment Satisfaction in Patients With PAH Rapidly Switched From Epoprostenol to Remodulin

Pulmonary Hypertension

United States
United Therapeutics

Completed

TRUST-2: Safety and Efficacy of Intravenous Remodulin® in Patients in India With Pulmonary Arterial Hypertension (PAH) (TRUST-2)

Pulmonary Arterial Hypertension
United Therapeutics

Completed

EXPEDITE: A Study of Remodulin Induction Followed by Orenitram Optimization to Treat Pulmonary Arterial Hypertension

Pulmonary Arterial Hypertension

United States
United Therapeutics
CVie Therapeutics Co. Ltd.

Withdrawn

An Open Label Extension Study to Evaluate the Safety of Continued Therapy of Subcutanous Remodulin® in Pulmonary Arterial Hypertension

Pulmonary Arterial Hypertension

China
United Therapeutics
University of Pittsburgh Medical Center

Withdrawn

Safety and Efficacy of Perioperative Remodulin® in Orthotopic Liver Transplant Recipients

Liver Transplant

United States
Magdi H. Yacoub

Recruiting

Effects of Treprostinil on Right Ventricular Structure and Function in Patients With Pulmonary Arterial Hypertension

Pulmonary Hypertension

Egypt
Medtronic Cardiac Rhythm and Heart Failure
United Therapeutics

Withdrawn

Implantable System for Remodulin Post-Approval Study (ISR PAS)

Pulmonary Arterial Hypertension
United Therapeutics

Completed

Safety and Tolerability of Rapid Dose Titration of Subcutaneous Remodulin® Therapy in PAH Subjects (RAPID) (RAPID)

Pulmonary Arterial Hypertension
Jewish General Hospital

Withdrawn

Hypotonic Treprostinil Subcutaneous Infusion for Control of Treprostinil Related Site Pain

Pulmonary Arterial Hypertension

Canada
Rajan Saggar
United Therapeutics

Completed

Treprostinil Therapy For Patients With Interstitial Lung Disease And Severe Pulmonary Arterial Hypertension

Idiopathic Pulmonary Fibrosis | Pulmonary Arterial Hypertension | Interstitial Lung Disease

United States
University Hospital, Grenoble

Terminated

Iontophoresis of Treprostinil to Enhance Wound Healing in Diabetic Foot Skin Ulcers (InTREPiD)

Diabetic Foot Ulcer

France
Shanghai Jiao Tong University School of Medicine

Completed

Study of Remodulin® in Pediatric Pulmonary Hypertension With Single Ventricular Physiology After Fontan Surgery

Pulmonary Hypertension
University of California, Los Angeles
United Therapeutics

Withdrawn

Efficacy of Remodulin in Adults With Congenital Heart Disease (ACHD) and Pulmonary Hypertension

Congenital Heart Disease

United States
United Therapeutics
University of California, Los Angeles; Emory University; Brigham and Women's... and other collaborators

Completed

A Study to Assess the Safety and Efficacy of Treprostinil to Facilitate Liver Transplantation in Patients With Portopulmonary Hypertension

Pulmonary Arterial Hypertension | Pulmonary Hypertension | Portopulmonary Hypertension

United States
United Therapeutics
Lung Biotechnology PBC

Recruiting

A Study of a Mean Pulmonary Artery Pressure-Targeted Approach With Early and Rapid Treprostinil Therapy to Reverse Right Ventricular Remodeling in Participants With Pulmonary Arterial Hypertension (ARTISAN)

Pulmonary Arterial Hypertension

United States
Stanford University

Terminated

Perioperative Treprostinil in Pediatric Patients Undergoing the Fontan Operation

Single Ventricle

United States
United Therapeutics
CVie Therapeutics Co. Ltd.

Withdrawn

Safety, Tolerability, Pharmacokinetics and Efficacy of Two Different Rates of Subcutanous Remodulin® Dose Titration in Pulmonary Arterial Hypertension

Pulmonary Arterial Hypertension

China
United Therapeutics

Terminated

Safety, Efficacy, and Treatment Satisfaction Switching From Flolan to Remodulin Using the Crono Five Ambulatory Pump in Patients With PAH

Pulmonary Arterial Hypertension

United States
Rhode Island Hospital
United Therapeutics; University of Rhode Island

Recruiting

Safety and Efficacy of Treprostinil (Remodulin®) In Reducing Ischemia-Reperfusion Injury During Kidney Transplantation

Ischemia Reperfusion Injury | Delayed Graft Function

United States
University of Arizona

Unknown

Trial to Evaluate Parenteral Treprostinil and Riociguat on Right Ventriculo-vascular Coupling and Morphology in Those With Advanced PAH

Pulmonary Arterial Hypertension

United States
Abhinav Humar, MD

Completed

Safety and Efficacy of Treprostinil in Ischemia and Reperfusion Injury in Adult Orthotopic Liver Transplantation

Ischemia Reperfusion Injury

United States
United Therapeutics

Active, not recruiting

Evaluate Real-World Use of Next Generation Infusion Pumps to Administer Remodulin (EVOLVE)

Pulmonary Arterial Hypertension

United States
SciPharm SàRL

Completed

Efficacy and Tolerability of Subcutaneously Administered Treprostinil Sodium in Patients With Severe (Non-operable) Chronic Thromboembolic Pulmonary Hypertension (CTREPH) (CTREPH)

Non-operable Chronic Thromboembolic Pulmonary Hypertension

Austria, Poland, Czechia, Germany
Medtronic Cardiac Rhythm and Heart Failure
United Therapeutics

Active, not recruiting

DelIVery for Pulmonary Arterial Hypertension (PAH) & Continued Support Study (DelIVery)

Pulmonary Arterial Hypertension

United States
Lung Biotechnology PBC

Terminated

Effects of Inhaled Treprostinil Sodium for the Treatment of Pulmonary Hypertension Associated With Idiopathic Pulmonary Fibrosis

Idiopathic Pulmonary Fibrosis | Pulmonary Hypertension

United States
United Therapeutics

Completed

A Transition Study From Flolan® to Remodulin® in Patients With Pulmonary Arterial Hypertension

Pulmonary Arterial Hypertension | Pulmonary Hypertension

United States
United Therapeutics

Terminated

Transitioning To IV Remodulin From Ventavis in Patients With PAH: Safety, Efficacy and Treatment Satisfaction

Hypertension, Pulmonary

United States
United Therapeutics

Terminated

Remodulin as Add-on Therapy for the Treatment of Persistent Pulmonary Hypertension of the Newborn

Persistent Pulmonary Hypertension of the Newborn

United States
AOP Orphan Pharmaceuticals AG
GCP-Service International Ltd. & Co. KG; ANOVA CRO s.r.o.; PharmaLex Belgium; Aixial...

Recruiting

Initial Triple Therapy Including Parenteral Treprostinil vs Initial Double Oral Therapy in PAH Group I Patients (TripleTRE)

Pulmonary Arterial Hypertension

Austria, Spain, France, Germany, Italy, Czechia, Hungary, Poland, Portugal, Romania
United Therapeutics

Terminated

Open-label Extension of Oral Treprostinil in Subjects With PH Associated With HFpEF

Pulmonary Hypertension Associated With HFpEF

United States
United Therapeutics

Completed

An Open-Label Extension Trial of UT-15C Sustained-release (SR) in Subjects With Pulmonary Arterial Hypertension (FREEDOM-EXT)

Pulmonary Arterial Hypertension

United States, Canada, India, United Kingdom, Spain, Israel, Australia, Belgium, France, Austria, China, Germany, Ireland, Italy, Mexico, Netherlands, Poland, Portugal, Puerto Rico, Sweden
United Therapeutics

Terminated

Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Heart Failure With Preserved Ejection Fraction

Pulmonary Hypertension | Heart Failure With Preserved Ejection Fraction

United States
United Therapeutics

Active, not recruiting

ADAPT - A Patient Registry of the Real-world Use of Orenitram® (ADAPT)

Pulmonary Arterial Hypertension

United States
United Therapeutics

Completed

Study of Incidence of Respiratory Tract AEs in Patients Treated With Tyvaso® Compared to Other FDA Approved PAH Therapies (Aspire)

Pulmonary Arterial Hypertension

United States
United Therapeutics

Recruiting

Multinational Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis (TETON-2)

Idiopathic Pulmonary Fibrosis | Interstitial Lung Disease

Taiwan, Belgium, Spain, Korea, Republic of, Germany, Australia, Chile, Denmark, France, Mexico, Israel, Italy, Netherlands, Argentina, New Zealand, Peru
United Therapeutics

Enrolling by invitation

Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis (TETON-OLE)

Idiopathic Pulmonary Fibrosis | Interstitial Lung Disease

United States, Spain, Australia, Taiwan, Israel, Korea, Republic of, Belgium, France, Argentina, Chile, Denmark, Mexico
Insmed Incorporated

Completed

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of C16TR for Inhalation With Tyvaso® Cohort in Healthy Participants

Healthy Volunteers

United States
United Therapeutics

Completed

FREEDOM - M: Oral Treprostinil as Monotherapy for the Treatment of Pulmonary Arterial Hypertension (PAH)

Pulmonary Hypertension

United States, China, Israel, Belgium, Canada, France, India, Mexico, Austria, Italy, Netherlands, Poland, Puerto Rico
United Therapeutics

Recruiting

Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)

Interstitial Lung Disease | Progressive Pulmonary Fibrosis

United States, Canada
United Therapeutics

Terminated

Open-Label Study of Oral Treprostinil in Digital Ulcers (DISTOL-EXT)

Systemic Sclerosis

United States, Canada, United Kingdom
United Therapeutics

Completed

Comparative Bioavailability of Treprostinil Diethanolamine Manufactured by Two Independent Facilities

Pulmonary Arterial Hypertension

United States
United Therapeutics

Completed

Effect of Food on the Pharmacokinetics of Oral Treprostinil

Pulmonary Arterial Hypertension | Hypertension, Pulmonary

United States
United Therapeutics

Completed

Three Times Daily Dosing of UT-15C

Healthy

United States
Insmed Incorporated

Terminated

A Study of Treprostinil Palmitil Inhalation Powder (TPIP) In Pulmonary Arterial Hypertension (PAH)

Pulmonary Arterial Hypertension

United States
United Therapeutics

Terminated

An Open Label Extension Study to Evaluate Inhaled Treprostinil in Adult PH With ILD Including CPFE

Pulmonary Hypertension | Interstitial Lung Disease | Combined Pulmonary Fibrosis and Emphysema

United States, Puerto Rico

Search clinical trials for: Remodulin (treprostinil sodium)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Georgia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations